# Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

Study · id `cardio:ct-nct06676384` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06676384](<https://clinicaltrials.gov/study/NCT06676384>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06676384

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 585 participants.

## Technical summary

Registry record NCT06676384. Randomized; single masking; primary purpose treatment. Start 2025-02-15 (actual); primary completion 2029-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 585 participants (planned count; ClinicalTrials.gov record NCT06676384, source copy `cardio:ctgov-nct06676384-2025-07-14`, retrieved 2026-10-26)
- Started: 2025-02-15 (actual) (ClinicalTrials.gov record NCT06676384, source copy `cardio:ctgov-nct06676384-2025-07-14`, retrieved 2026-10-26)
- Primary completion: 2029-08 (anticipated) (ClinicalTrials.gov record NCT06676384, source copy `cardio:ctgov-nct06676384-2025-07-14`, retrieved 2026-10-26)
- Completion: 2029-08 (anticipated) (ClinicalTrials.gov record NCT06676384, source copy `cardio:ctgov-nct06676384-2025-07-14`, retrieved 2026-10-26)
- Countries: India (ClinicalTrials.gov record NCT06676384, source copy `cardio:ctgov-nct06676384-2025-07-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06676384-2025-07-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
- Acronym: IA-GRACE-IgANT
- Condition: IgA Nephropathy
- Condition: Renal Insufficiency, Chronic
- Condition: IgA Vasculitis
- Condition: IGA Glomerulonephritis
- Intervention (Drug): Oral prednisolone and SoC
- Intervention (Drug): Gut-directed budesonide and SoC
- Intervention (Drug): Mycophenolate mofetil (MMF) and SoC
- Intervention (Drug): Hydroxychloroquine and SoC
- Intervention (Drug): Non-steroidal mineralocorticoid receptor antagonist and SoC
- Intervention (Drug): SoC defined as maximal labelled or tolerated dose of angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker (ACEi/ARB) & steady dose of sodium-glucose cotransporter-2 inhibitor (SGLT2i)
- Lead sponsor: Christian Medical College, Vellore, India
- Lead sponsor class: OTHER
- Collaborator: Medical Research Council
- Collaborator class: OTHER\_GOV
- Collaborator: India Alliance
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Christian Medical College, Vellore, India (`cardio:org-christian-medical-college-vellore-india`)
- Registry lists this organization as a collaborator: Medical Research Council (United Kingdom) (`cardio:mrc`)

## Provenance

Content hash: f404a2a63593cabbc9d15645e967a0ffdb64ac03a2e48c32cb6bc581899c7bf9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
